Latest Breaking News On - Regulatory authorization - Page 1 : comparemela.com

Multiple System Atrophy (MSA) Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline as Leading 20+ Companies Working in the Domain |

Inovio Pharmaceuticals Inc. [INO] stock Downgrade by BofA Securities analyst, price target now $8

Inovio Pharmaceuticals Inc. [NASDAQ: INO] plunged by -$0.38 during the normal trading session on Thursday and reaching a high of $7.41 during the day while it closed the day at $7.08. The company report on November 3, 2021 that INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine C

Inovio Pharmaceuticals Inc. (INO) distance from 20-day Simple moving Average is -8.88%: What to Expect?

Inovio Pharmaceuticals Inc. (INO) is priced at $7.39 after the most recent trading session. At the very opening of the session, the stock price was $7.80 and reached a high price of $7.90, prior to closing the session it reached the value of $7.77. The stock touched a low price of $7.69.Recently in

Hyderabad's Biological E set to give fourth vaccine for India

Hyderabad’s Biological E set to give fourth vaccine for India By M Somasekhar|   Updated: 23rd April 2021 9:13 pm IST M Somasekhar Hyderabad: Biological E, the country’s first manufacturer of vaccines in the private sector is all set to launch India’s fourth vaccine against COVID 19 by August 2021. According to the Indian Council of Medical Research( ICMR) , Biological E is testing a two-dose vaccine similar to ‘Covaxin’, made by Bharat Biotech, another Hyderabad -based, vaccine maker. The Niti Aayog member (health) Dr V K Paul recently said, “Biological E has finished phase-1/2 trials. They are submitting the data in the next few days after which they will initiate phase-3 trials of the vaccine.”

Groupe BPCE - PRESS RELEASE RELATING TO THE AVAILABILITY OF THE OFFER DOCUMENT PREPARED BY BPCE